226 related articles for article (PubMed ID: 29575526)
1. Fatty Acid Amide Hydrolase Inhibition by JNJ-42165279: A Multiple-Ascending Dose and a Positron Emission Tomography Study in Healthy Volunteers.
Postnov A; Schmidt ME; Pemberton DJ; de Hoon J; van Hecken A; van den Boer M; Zannikos P; van der Ark P; Palmer JA; Rassnick S; Celen S; Bormans G; van Laere K
Clin Transl Sci; 2018 Jul; 11(4):397-404. PubMed ID: 29575526
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and biological properties of 4-(3-phenyl-[1,2,4] thiadiazol-5-yl)-piperazine-1-carboxylic acid phenylamide, a mechanism-based inhibitor of fatty acid amide hydrolase.
Karbarz MJ; Luo L; Chang L; Tham CS; Palmer JA; Wilson SJ; Wennerholm ML; Brown SM; Scott BP; Apodaca RL; Keith JM; Wu J; Breitenbucher JG; Chaplan SR; Webb M
Anesth Analg; 2009 Jan; 108(1):316-29. PubMed ID: 19095868
[TBL] [Abstract][Full Text] [Related]
3. Blocking of fatty acid amide hydrolase activity with PF-04457845 in human brain: a positron emission tomography study with the novel radioligand [(11)C]CURB.
Boileau I; Rusjan PM; Williams B; Mansouri E; Mizrahi R; De Luca V; Johnson DS; Wilson AA; Houle S; Kish SJ; Tong J
J Cereb Blood Flow Metab; 2015 Nov; 35(11):1827-35. PubMed ID: 26082009
[TBL] [Abstract][Full Text] [Related]
4. [11C]CURB: Evaluation of a novel radiotracer for imaging fatty acid amide hydrolase by positron emission tomography.
Wilson AA; Garcia A; Parkes J; Houle S; Tong J; Vasdev N
Nucl Med Biol; 2011 Feb; 38(2):247-53. PubMed ID: 21315280
[TBL] [Abstract][Full Text] [Related]
5. Development of an In Vivo Method to Estimate Effective Drug Doses and Quantify Fatty Acid Amide Hydrolase in Rodent Brain using Positron Emission Tomography Tracer [
Yamasaki T; Ohya T; Mori W; Zhang Y; Wakizaka H; Nengaki N; Fujinaga M; Kikuchi T; Zhang MR
J Pharmacol Exp Ther; 2020 Jun; 373(3):353-360. PubMed ID: 32241809
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH).
Chen Z; Hou L; Gan J; Cai Q; Ye W; Chen J; Tan Z; Zheng C; Li G; Xu H; Fowler CJ; Liang SH; Wang L
Bioorg Med Chem Lett; 2020 Nov; 30(21):127513. PubMed ID: 32860981
[TBL] [Abstract][Full Text] [Related]
7. Fatty Acid Amide Hydrolase Binding in Brain of Cannabis Users: Imaging With the Novel Radiotracer [
Boileau I; Mansouri E; Williams B; Le Foll B; Rusjan P; Mizrahi R; Tyndale RF; Huestis MA; Payer DE; Wilson AA; Houle S; Kish SJ; Tong J
Biol Psychiatry; 2016 Nov; 80(9):691-701. PubMed ID: 27345297
[TBL] [Abstract][Full Text] [Related]
8. The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study.
Schmidt ME; Liebowitz MR; Stein MB; Grunfeld J; Van Hove I; Simmons WK; Van Der Ark P; Palmer JA; Saad ZS; Pemberton DJ; Van Nueten L; Drevets WC
Neuropsychopharmacology; 2021 Apr; 46(5):1004-1010. PubMed ID: 33070154
[TBL] [Abstract][Full Text] [Related]
9. The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP3652 in First-in-Human and Ascending Multiple Oral Dose Studies in Healthy Subjects.
Takizawa M; Cerneus D; Michon I; Rijnders S; van der Heide D; Meijer J; Stoelzel M; Sato Y
Adv Ther; 2020 Sep; 37(9):3878-3900. PubMed ID: 32681461
[TBL] [Abstract][Full Text] [Related]
10. Piperazine and piperidine carboxamides and carbamates as inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
Korhonen J; Kuusisto A; van Bruchem J; Patel JZ; Laitinen T; Navia-Paldanius D; Laitinen JT; Savinainen JR; Parkkari T; Nevalainen TJ
Bioorg Med Chem; 2014 Dec; 22(23):6694-6705. PubMed ID: 25282655
[TBL] [Abstract][Full Text] [Related]
11. N-(3,4-Dimethylisoxazol-5-yl)piperazine-4-[4-(2-fluoro-4-[(11)C]methylphenyl)thiazol-2-yl]-1-carboxamide: A promising positron emission tomography ligand for fatty acid amide hydrolase.
Shimoda Y; Fujinaga M; Hatori A; Yui J; Zhang Y; Nengaki N; Kurihara Y; Yamasaki T; Xie L; Kumata K; Ishii H; Zhang MR
Bioorg Med Chem; 2016 Feb; 24(4):627-34. PubMed ID: 26740152
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of fatty acid amide hydrolase by BIA 10-2474 in rat brain.
Tong J; Mizrahi R; Houle S; Kish SJ; Boileau I; Nobrega J; Rusjan PM; Wilson AA
J Cereb Blood Flow Metab; 2017 Nov; 37(11):3635-3639. PubMed ID: 27650910
[TBL] [Abstract][Full Text] [Related]
13. Benzylamides and piperazinoarylamides of ibuprofen as fatty acid amide hydrolase inhibitors.
Deplano A; Cipriano M; Moraca F; Novellino E; Catalanotti B; Fowler CJ; Onnis V
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):562-576. PubMed ID: 30688118
[TBL] [Abstract][Full Text] [Related]
14. PET imaging of fatty acid amide hydrolase in the brain: synthesis and biological evaluation of an 11C-labelled URB597 analogue.
Wyffels L; Muccioli GG; Kapanda CN; Labar G; De Bruyne S; De Vos F; Lambert DM
Nucl Med Biol; 2010 Jul; 37(5):665-75. PubMed ID: 20610171
[TBL] [Abstract][Full Text] [Related]
15. Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.
Walentiny DM; Vann RE; Wiley JL
Neuropharmacology; 2015 Jun; 93():237-42. PubMed ID: 25698527
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and preclinical evaluation of [11C-carbonyl]PF-04457845 for neuroimaging of fatty acid amide hydrolase.
Hicks JW; Parkes J; Sadovski O; Tong J; Houle S; Vasdev N; Wilson AA
Nucl Med Biol; 2013 Aug; 40(6):740-6. PubMed ID: 23731552
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo pharmacological characterization of ASP8477: A novel highly selective fatty acid amide hydrolase inhibitor.
Watabiki T; Tsuji N; Kiso T; Ozawa T; Narazaki F; Kakimoto S
Eur J Pharmacol; 2017 Nov; 815():42-48. PubMed ID: 29017758
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics and safety studies on URB937, a peripherally restricted fatty acid amide hydrolase inhibitor, in rats.
Vozella V; Ahmed F; Choobchian P; Merrill CB; Zibardi C; Tarzia G; Mor M; Duranti A; Tontini A; Rivara S; Piomelli D
J Pharm Pharmacol; 2019 Dec; 71(12):1762-1773. PubMed ID: 31579946
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M; Ravenstijn P; Xi L; Triana-Baltzer G; Furey M; Van Hemelryck S; Biewenga J; Ceusters M; Bhattacharya A; van den Boer M; van Nueten L; de Boer P
J Psychopharmacol; 2018 Dec; 32(12):1341-1350. PubMed ID: 30260294
[TBL] [Abstract][Full Text] [Related]
20. Fatty acid amide hydrolase inhibitors: a patent review (2009-2014).
Lodola A; Castelli R; Mor M; Rivara S
Expert Opin Ther Pat; 2015; 25(11):1247-66. PubMed ID: 26413912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
